2022
Bidirectional relationships between cannabis use, anxiety and depressive symptoms in the mediation of the association with psychotic experience: further support for an affective pathway to psychosis
Radhakrishnan R, Pries LK, Erzin G, Have M, de Graaf R, van Dorsselaer S, Gunther N, Bak M, Rutten BPF, van Os J, Guloksuz S. Bidirectional relationships between cannabis use, anxiety and depressive symptoms in the mediation of the association with psychotic experience: further support for an affective pathway to psychosis. Psychological Medicine 2022, 53: 5551-5557. PMID: 36093677, PMCID: PMC10482707, DOI: 10.1017/s0033291722002756.Peer-Reviewed Original ResearchConceptsAnxiety/depressive symptomsDepressive symptomsCannabis usePE incidencePsychotic experiencesFirst longitudinal cohort studyNetherlands Mental Health SurveyLongitudinal cohort studyMental Health SurveyRole of cannabisBidirectional relationshipCohort studyHealth SurveyIncidence studyAffective symptomsSymptomsCannabisEducation statusLongitudinal studyPsychosisIncidenceAnxietyTemporal relationshipMediation analysisFurther supportThe association between cannabis use and facial emotion recognition in schizophrenia, siblings, and healthy controls: Results from the EUGEI study
Fusar-Poli L, Pries LK, van Os J, Radhakrishnan R, Pençe AY, Erzin G, Delespaul P, Kenis G, Luykx JJ, Lin BD, Akdede B, Binbay T, Altınyazar V, Yalınçetin B, Gümüş-Akay G, Cihan B, Soygür H, Ulaş H, Cankurtaran EŞ, Kaymak SU, Mihaljevic MM, Andric-Petrovic S, Mirjanic T, Bernardo M, Mezquida G, Amoretti S, Bobes J, Saiz PA, García-Portilla MP, Sanjuan J, Aguilar EJ, Santos JL, Jiménez-López E, Arrojo M, Carracedo A, López G, González-Peñas J, Parellada M, Maric NP, Atbaşoğlu C, Üçok A, Alptekin K, Saka MC, investigators G, Aguglia E, Arango C, Rutten BP, Guloksuz S. The association between cannabis use and facial emotion recognition in schizophrenia, siblings, and healthy controls: Results from the EUGEI study. European Neuropsychopharmacology 2022, 63: 47-59. PMID: 36055075, DOI: 10.1016/j.euroneuro.2022.08.003.Peer-Reviewed Original ResearchConceptsHealthy controlsCannabis useDegraded Facial Affect Recognition TaskPresent cross-sectional studyCross-sectional studyHigh genetic riskProgression of schizophreniaRegular cannabis useCognitive disturbancesRegular cannabisPsychosis riskPatientsSchizophreniaFacial emotion recognition performanceGenetic riskCannabisCurrent cannabisEUGEI studyLongitudinal studyAgeSiblingsAssociationRiskOnsetEffect relationshipEditorial: Gone to Pot: Examining the Association Between Cannabis Use and Medical/Psychiatric Disorders
Radhakrishnan R, Guloksuz S, D'Souza DC, van Os J. Editorial: Gone to Pot: Examining the Association Between Cannabis Use and Medical/Psychiatric Disorders. Frontiers In Psychiatry 2022, 13: 837757. PMID: 35211046, PMCID: PMC8861305, DOI: 10.3389/fpsyt.2022.837757.Peer-Reviewed Original ResearchPsychiatric disordersCannabis use
2019
20. ELUCIDATING THE LINK BETWEEN CANNABIS USE AND PSYCHOSIS: FROM THE EXPOSOME AND PHENOME TO THE EPIGENOME AND RECEPTOME
Radhakrishnan R. 20. ELUCIDATING THE LINK BETWEEN CANNABIS USE AND PSYCHOSIS: FROM THE EXPOSOME AND PHENOME TO THE EPIGENOME AND RECEPTOME. Schizophrenia Bulletin 2019, 45: s121-s121. PMCID: PMC6455407, DOI: 10.1093/schbul/sbz022.079.Peer-Reviewed Original ResearchFirst-episode psychosisCannabis useReceptor availabilityEU-GEIMeasures of information processingHealthy controlsEU-GEI studyCannabis use resultsPsychosis-spectrum disordersCannabis use disorderPhenotype of schizophreniaRelevant to psychosisRegular cannabis useBrain imaging studiesAssociated with schizophreniaAssessment of behaviorMulti-modal imaging studyPersistent psychosisPsychosis expressionCB1 receptorsCannabis exposureMemory encodingUse disorderPsychosisSchizophrenia
2018
Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial
D'Souza DC, Cortes-Briones J, Creatura G, Bluez G, Thurnauer H, Deaso E, Bielen K, Surti T, Radhakrishnan R, Gupta A, Gupta S, Cahill J, Sherif MA, Makriyannis A, Morgan PT, Ranganathan M, Skosnik PD. Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial. The Lancet Psychiatry 2018, 6: 35-45. PMID: 30528676, DOI: 10.1016/s2215-0366(18)30427-9.Peer-Reviewed Original ResearchConceptsPF-04457845Cannabis withdrawal symptomsFatty acid amide hydrolaseCannabis withdrawalPlacebo groupAdverse eventsCannabis useWithdrawal symptomsFatty acid amide hydrolase inhibitorSerious adverse eventsPhase 2a trialWeeks of treatmentTreatment of cannabisCannabis use disorderSelf-reported cannabis useDSM-IV criteriaTreatment-related differencesTHC-COOH concentrationsAnandamide concentrationsTreat populationPrimary endpointPill countHospital admissionNovel FAAH inhibitorsSelf-reported cannabis
2012
Acute effects of THC on time perception in frequent and infrequent cannabis users
Sewell RA, Schnakenberg A, Elander J, Radhakrishnan R, Williams A, Skosnik PD, Pittman B, Ranganathan M, D’Souza D. Acute effects of THC on time perception in frequent and infrequent cannabis users. Psychopharmacology 2012, 226: 401-413. PMID: 23179965, PMCID: PMC3581701, DOI: 10.1007/s00213-012-2915-6.Peer-Reviewed Original ResearchConceptsCannabis smokersAcute effectsFrequent cannabis smokersPlacebo-controlled studyCannabis usersChronic cannabis smokersInfrequent cannabis usersWhole-plant cannabisChronic cannabis useResultsAll dosesVariable pharmacokineticsBlunted responseSubjects three timesHigh dosesTHC effectsFrequent cannabis usersCannabis useInternal clock speedΔ9-tetrahydrocannabinolSmall sample sizeDosesFrequent cannabisThree timesTest daySmokers